Draft legislation introduced in the US by senator Mike Lee is seeking to “increase competition within the biological drug market and reduce consumer costs” by prohibiting the US Food and Drug Administration from requiring biosimilars to undergo switching studies to receive an interchangeability designation.
According to Lee, the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?